Tensile hypertension (HF) occurs in adolescents with a frequency of 10-13%. Subclinical organ lesions (left ventricular hypertrophy, microalbuminuria, hypertensive changes at the fundus of the eyes, changes in the taffin) are found in half of these patients at the time of diagnosis of hypertension and hypertension in the second decade of life is a significant risk factor for liver problems, strokes and renal failure in adulthood .
Conditions
Brief summary
Number of patients whose blood pressure normalised arterial disease assessed in an office measurement at the end of the second study period (week 6) in each group (A-B), Number of patients whose blood pressure normalised arterial disease assessed by office measurement in the Ill study period (week 38), the number of patients with adverse events and serious adverse events at the end of Study Period II in each group (A-B)., the number of patients who had adverse events and serious adverse events during the Ill study period.
Detailed description
Number of patients whose blood pressure normalised in ABPM at the end of Study Period II (week 6) in each group (A-B) and in Ill Period in all patients (week 38), change in mean and percentile (Z-score) of systolic, diastolic and mean blood pressure assessed in the office measurement and in the ABPM study in the II study period (6 weeks) in each group (A-B) and in the Ill study period (38 weeks) in the study group, Number of patients who achieved normalization of blood pressure as measured at home (HBPM) during the last week of the II study period in each group (A-B) and at the last week of the Ill study period in all patients (week 38)
Interventions
Sponsors
Medical University Of Warsaw
Eligibility
Sex/Gender
All
Age
0 Years to 17 Years
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Number of patients whose blood pressure normalised arterial disease assessed in an office measurement at the end of the second study period (week 6) in each group (A-B), Number of patients whose blood pressure normalised arterial disease assessed by office measurement in the Ill study period (week 38), the number of patients with adverse events and serious adverse events at the end of Study Period II in each group (A-B)., the number of patients who had adverse events and serious adverse events during the Ill study period. | — |
Secondary
| Measure | Time frame |
|---|---|
| Number of patients whose blood pressure normalised in ABPM at the end of Study Period II (week 6) in each group (A-B) and in Ill Period in all patients (week 38), change in mean and percentile (Z-score) of systolic, diastolic and mean blood pressure assessed in the office measurement and in the ABPM study in the II study period (6 weeks) in each group (A-B) and in the Ill study period (38 weeks) in the study group, Number of patients who achieved normalization of blood pressure as measured at home (HBPM) during the last week of the II study period in each group (A-B) and at the last week of the Ill study period in all patients (week 38) | — |
Countries
Poland
Outcome results
None listed